Publications
132
Citations
788
Est. group size
~32
Recurring co-author estimate
Active years
15
Publishing since 2012
Ashish Manne's research centers on gastrointestinal cancers, especially pancreatic ductal adenocarcinoma, hepatocellular carcinoma, and colorectal cancer, with a focus on identifying biomarkers, understanding tumor biology, and improving treatment strategies. Work spans genomic and transcriptomic profiling, blood-based (ctDNA) monitoring, immunotherapy approaches, and use of AI to link tissue imaging with genetic mutations, often incorporating studies of disparities across patient demographic groups. Much of the output involves clinical and translational studies, systematic reviews, and conference abstracts related to novel therapeutics and combination treatments.
Publication output has grown substantially over the last decade, rising from just a few papers per year before 2020 to over 40 in 2025, indicating an actively expanding research program.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- 437 Bridging Histology and Genomics: Artificial Intelligence (AI) Predicts Colorectal Cancer Genetic Mutations from H&E Images
Laboratory Investigation · 2026
- Serial ctDNA dynamics predict clinical outcomes in metastatic and locally advanced PDAC: A Systematic Review
2026
- Transcriptomic profiling and demographic analysis of Appalachian and non-Appalachian patients with pancreatic ductal adenocarcinoma using the Purity Independent Subtyping of Tumors Classifier.
Journal of Clinical Oncology · 2026
- Abstract 1043: MUC5AC expression defines an immune-inflamed but functionally restrained tumor microenvironment in pancreatic ductal adenocarcinoma
Cancer Research · 2026
- Abstract 7719: Exploring biomarker predictors of response to nintedanib and bevacizumab combination therapy in advanced cancer patients: Correlative studies from Phase 1b study
Cancer Research · 2026
- Biliary neuroendocrine tumors: a narrative review of current diagnostics and management strategies
Chinese Clinical Oncology · 2026
- Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies
Cancers · 2025
- Blood-based biomarkers in pancreatic ductal adenocarcinoma: developments over the last decade and what holds for the future- a review
Frontiers in Oncology · 2025
- Large Language Models for Drug-Related Adverse Events in Oncology Pharmacy: Detection, Grading, and Actioning
Pharmacy · 2025
- Novel Therapeutics for Hepatocellular Carcinoma
Clinics in Liver Disease · 2025
- Predictive methylation signature for gemcitabine sensitivity in pancreatic ductal adenocarcinoma: A pathway to personalized treatment.
Journal of Clinical Oncology · 2025
- More isn't always better: Expanding and refining prognostic methylation signatures for pancreatic ductal adenocarcinoma.
Journal of Clinical Oncology · 2025
- Differential Gene Expression Profiles of Pancreatic Ductal Adenocarcinomas Among African American and Caucasian American Patients
SSRN Electronic Journal · 2025
- Ripretinib versus sunitinib in imatinib-resistant gastro-intestinal stromal tumor with KIT Exon 11 mutations: A systematic review and meta-analysis.
Journal of Clinical Oncology · 2025
- P4HA1 Activates Mtorc1, Confers FOLFIRINOX Therapy Resistance, and Suppresses Anti-Tumor Immunity in Pancreatic Ductal Adenocarcinoma
SSRN Electronic Journal · 2025
- Journal of Clinical Oncology×53
- Cancers×10
- Cancer Research×8
- Frontiers in Oncology×4
- International Journal of Molecular Sciences×3
- Susan Tsai
Medicine · The Ohio State University
- Anne M. Noonan
Medicine · The Ohio State University
- Sean P. Cleary
Medicine · The Ohio State University
- Susan Tsai
Medicine · The Ohio State University
- Matthew J. Weiss
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile